Last reviewed · How we verify
NCT06044818
Validation of Accexible as a Tool for Screening and Monitoring Depression.
trial testing Accexible in Major Depressive Disorder (MDD) in 166 participants. Completed in 17 April 2025.
17 April 2025
Quick facts
| Lead sponsor | Accexible |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 166 |
| Start date | 10 July 2023 |
| Primary completion | 17 April 2025 |
| Estimated completion | 17 April 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Accexible
Conditions studied
- Major Depressive Disorder (MDD) — all drugs for Major Depressive Disorder (MDD) →
Sponsor
Accexible — full company profile →
Who can join
Adults 18 to 65, any sex, with Major Depressive Disorder (MDD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Major depressive disorder (MDD) is a chronic disease with a prevalence around 8-12% and is considered one of the most debilitating disease worldwide. A recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. It can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness. The present study has the objective of validating Accexible as a tool for Screening and Monitoring Depression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06044818
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Accexible
Trials testing the same drug.
- NCT05534958 — UK Validation of the Automated "AcceXible" Speech Analysis Software · completed
Other recruiting trials for Major Depressive Disorder (MDD)
Currently open trials in the same condition.
- NCT07396272 — A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression · Phase 2 · recruiting
- NCT07226661 — Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder · Phase 2 · recruiting
- NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
- NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
- NCT07294924 — Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements · recruiting
Other Accexible trials
Trials by the same sponsor.
- NCT05534958 — UK Validation of the Automated "AcceXible" Speech Analysis Software · completed
- NCT05380297 — Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild · NA · completed
- NCT05340218 — Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06044818 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Accexible
- Last refreshed: 25 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06044818.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing